Evaluation of Platelet Inhibition by Tirofiban in Patients Stratified According to Aspirin and Clopidogrel Responsiveness: The 3T/2R (Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel)

[...]inclusion and exclusion criteria, study design, screening procedure, definitions, primary end point, and sample size have been previously reported (4,5). [...]response to clopidogrel still remained suboptimal compared with that of full responders. [...]a strategy of GP IIb/IIIa inhibitor admini...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2010-01, Vol.55 (3), p.255-256
Main Authors: Campo, Gianluca, Valgimigli, Marco, Frangione, Alice, Luccarelli, Serena, Cangiano, Elisa, Cavazza, Caterina, Fileti, Luca, Ferrari, Roberto
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary - adverse effects
Aspirin
Aspirin - therapeutic use
Blood platelets
Cardiology
Cohort Studies
Drug Resistance
Drug therapy
Heart attacks
Humans
Mortality
Myocardial Infarction - epidemiology
Myocardial Infarction - prevention & control
Patient Selection
Platelet Aggregation Inhibitors - therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Tyrosine - analogs & derivatives
Tyrosine - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]inclusion and exclusion criteria, study design, screening procedure, definitions, primary end point, and sample size have been previously reported (4,5). [...]response to clopidogrel still remained suboptimal compared with that of full responders. [...]a strategy of GP IIb/IIIa inhibitor administration remains attractive to reduce the peri-procedural ischemic burden of high on-treatment PR, especially in clinical settings where delaying the procedure to allow more complete PI is not acceptable (3).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2009.08.052